A Study of LY2484595 on the Electrical Activity of the Heart

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect on the electrical activity of the heart as measured by an electrocardiogram (ECG) after dosing with 10 days of LY2484595 compared to 10 days of placebo in relation to a single dose of moxifloxacin. Information about any side effects that occur will also be collected.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Evacetrapib; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Healthy males and females

• Body mass index (BMI) of 18.5 to 29 kilograms per square meter (kg/m²)

• Reliable and willing to be available for the duration of the study and are willing to follow study procedures

• Provided written informed consent

Exclusion Criteria:

• Known allergies to LY2484595 or moxifloxacin

• Personal or family history of long QT syndrome, heart failure, or low blood potassium (hypokalemia) a family history of sudden death, or unexplained syncope within the last year

• Positive findings on urinary drug screening

• Cigarette smokers